)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Simris Group
Simris Group (SIMRIS) investor relations material
Simris Group Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary12 Aug, 2026
Executive summary
Net revenue for Q2 2026 fell 71% year-over-year to SEK 196k; interim period revenue down 27% to SEK 620k.
EBITDA loss improved 35% in Q2 to SEK -1,927k and 39% for the interim period to SEK -4,110k.
EBIT loss improved 19% in Q2 to SEK -5,437k and 21% for the interim period to SEK -11,063k.
Significant management changes: new CEO for Simris Biologics and a new strategic advisor appointed.
Divestment process for Hammenhög assets advanced with two prospective buyers.
Financial highlights
Cash at period end increased to SEK 7,987k from SEK 1,026k year-over-year.
Result before tax improved 17% in Q2 to SEK -6,751k and 8% for the interim period to SEK -13,724k.
Cash flow from operating activities in Q2 was SEK -2,554k, down 34% year-over-year.
Equity at period end was SEK 767k, up from SEK -7,745k a year earlier; solidity at 0.6%.
Outlook and guidance
Ongoing warrant exercise expected to raise approximately EUR 1 million, extending financial runway.
Board warns current cash reserves may not cover operations through year-end; active efforts underway to secure additional funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Simris Group
- Revenue up 167% year-over-year, but urgent funding needed to sustain operations.SIMRIS
Q1 2026 - Revenue declined sharply and liquidity is strained as the company pivots to biotech and seeks funding.SIMRISQ4 2025
- Revenue fell sharply and funding is urgent despite operational improvements and R&D progress.SIMRISQ3 2025
- EBITDA loss narrowed 51% in Q2, but liquidity remains a critical concern.SIMRISQ2 2025
- Revenue up, losses narrowed, but urgent funding needed amid leadership and strategic shifts.SIMRISQ3 2024
- EBITDA loss narrowed and new collaborations advanced Simris Group's ADC platform.SIMRISQ2 2024
- Revenue plunged, losses narrowed, and urgent funding is needed for continued operations.SIMRISQ1 2025
- Revenue fell, losses narrowed, and urgent funding is needed for continued operations.SIMRISQ4 2024
Next Simris Group earnings date
Q3 202611 Nov, 2026
Simris Group
Next Simris Group earnings date
Q3 202611 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Simris Group AB is a Swedish company specializing in the cultivation and commercialization of high-value bioactive compounds derived from microalgae and cyanobacteria. The company focuses on sustainable production methods using photobioreactor technology to grow these microorganisms on non-arable land, reducing environmental impact. Simris Group's product portfolio includes applications in skincare, nutrition, and biopharmaceuticals. Their advanced research and development initiatives have led to the identification of over 5,000 novel compounds with potential uses in cosmetics, agricultural products, and pharmaceuticals. The company is headquartered in Hammenhög, Sweden, and its shares are listed on the Stockholm Stock Exchange.